CNTX Stock Overview
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States.
Context Therapeutics Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.12|
|52 Week High||US$10.87|
|52 Week Low||US$1.06|
|1 Month Change||-40.43%|
|3 Month Change||-44.00%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-78.04%|
Recent News & Updates
Context to focus on ELONA trial, CLDN6 program, extends cash runway into 1Q24
Context Therapeutics (NASDAQ:CNTX) on Tuesday updated cash guidance to extend its runway into Q1 2024. The company plans to defer noncritical R&D activities, reduce future overhead and infrastructure expenditures, and prioritize its onapristone extended release (ONA-XR) ELONA Phase 1b/2 clinical trial and Claudin 6 (CLDN6) program. CNTX said it is evaluating ELONA clinical trial evaluating CNTX's oral progesterone receptor (PR) antagonist ONA-XR in combination with Menarini's elacestrant in estrogen receptor positive, PR+ HER2- metastatic breast cancer patients, who have previously been treated with a CDK4/6 inhibitor in Q4 this year and to report Phase 1b data in Q4 2023.
We're Keeping An Eye On Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Context Therapeutics GAAP EPS of -$0.25 in-line
Context Therapeutics press release (NASDAQ:CNTX): Q2 GAAP EPS of -$0.25 in-line. Cash, cash equivalents, and restricted cash were $42.9 million.
Context Therapeutics, Menarini to collaborate on breast cancer treatment combo trial
Context Therapeutics (NASDAQ:CNTX) and Italian pharmaceutical major Menarini Group have entered into a clinical trial collaboration and supply agreement to evaluate a breast cancer combination treatment, the companies said on Tuesday. The agreement will support the upcoming phase 1b/2 ELONA clinical trial evaluating CNTX's oral progesterone receptor (PR) antagonist ONA-XR in combination with Menarini's elacestrant in estrogen receptor positive, PR+ HER2- metastatic breast cancer patients who have previously been treated with a CDK4/6 inhibitor. Context (CNTX) will sponsor the trial while Menarini will supply elacestrant at no cost. CNTX said it anticipates starting the phase 1b/2 trial in Q4 this year. CNTX stock gained 5.8% to $2 in premarket trading.
Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|CNTX||US Pharmaceuticals||US Market|
Return vs Industry: Insufficient data to determine how CNTX performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how CNTX performed against the US Market.
|CNTX Average Weekly Movement||9.4%|
|Pharmaceuticals Industry Average Movement||11.2%|
|Market Average Movement||6.8%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: CNTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: CNTX's weekly volatility (9%) has been stable over the past year.
About the Company
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Context Therapeutics Inc. Fundamentals Summary
|CNTX fundamental statistics|
Is CNTX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CNTX income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.75|
|Net Profit Margin||0.00%|
How did CNTX perform over the long term?See historical performance and comparison